Trandolapril is an orally administered angiotensin converting enzyme (ACE) inhibitor that
has been used in the treatment of patients with hypertension and congestive heart failure …

Synopsis Trandolapril is a non-sulfhydryl prodrug which, after oral administration, is
hydrolysed in the liver to its active diacid, trandolaprilat. Trandolaprilat inhibits the …

Background: Trandolapril is a newer angiontensin-converting enzyme (ACE) inhibitor that is
approved by the US Food and Drug Administration for the treatment of hypertension and for …

Trandolapril is a well known angiotensin converting enzyme (ACE) inhibitor with many
cardiovascular (CV) indications. The objectives of this article are to review the …

The pharmacological activity and safety of the new angiotensin converting enzyme (ACE)
inhibitor trandolapril (RU 44570) has been evaluated in ten healthy male volunteers given 2 …

Trandolapril is a new anǵiotensin-converting enzyme (ACE) inhibitor that has been
extensively investigated in vitro, in animals, in normal volunteers, and in hypertensive …

An international trial recruited 1.049 patients from 122 investigators. After a 2− to 4-week,
single-blind placebo run-in, patients were treated unblinded for 1 year. Therapy was started …

Among the physicochemical, pharmacokinetic and pharmacodynamic properties that
differentiate trandolapril from other angiotensin converting enzyme (ACE) inhibitors, the …

Trandolapril is a newly developed angiotensin-converting enzyme (ACE) inhibitor that is
rapidly hydrolyzed mainly in the liver to its biologically active metabolite trandolaprilat. The …

The pharmacokinetics and dose proportionality of trandolapril, a new angiotensin-converting
enzyme (ACE) inhibitor, were investigated in 12 healthy male volunteers in a four-way …